Kavitha K. Prabaker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kavitha K. Prabaker has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Shangxin Yang
UCLA David Geffen School of Medicine
3 shared publications - Annabelle de St. Maurice
Division of Pediatric Infectious Diseases, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California
2 shared publications - Daniel Z. Uslan
UCLA David Geffen School of Medicine
2 shared publications - Omai B. Garner
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA
2 shared publications Ayrton J. Dayo
Department of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Los Angeles, California
1 shared publication- Bennett Shaw
UCLA David Geffen School of Medicine
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e360
Homogeneous antimicrobial resistance gene profiles despite phylogenetic diversity in carbapenem-resistant Acinetobacter baumannii : a single health system study in Los Angeles, 2019–2026
This study characterizes the clinical, genomic, and antimicrobial resistance profiles of thirty carbapenem-resistant A. baumannii isolates recovered from patients in a multi-hospital health system. Medical record review identified high proportion of patients with invasive devices, long-term facility exposure, and combination therapy. Genomic analysis demonstrated genomic diversity but homogeneous antimicrobial resistance profiles.
- 12 November 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e360
Open AccessHomogeneous antimicrobial resistance gene profiles despite phylogenetic diversity in carbapenem-resistant Acinetobacter baumannii : a single health system study in Los Angeles, 2019–2026
This study characterizes the clinical, genomic, and antimicrobial resistance profiles of thirty carbapenem-resistant A. baumannii isolates recovered from patients in a multi-hospital health system. Medical record review identified high proportion of patients with invasive devices, long-term facility exposure, and combination therapy. Genomic analysis demonstrated genomic diversity but homogeneous antimicrobial resistance profiles.
- 14 December 2022
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 107 (6) , 1258-1260
Case Report: Symptomatic Herpes Simplex Virus Type 2 and Monkeypox Coinfection in an Adult Male
A 39-year-old man presented with a history of fatigue, malaise, and rash with varied morphology on his perianal region. Polymerase chain reaction testing of the lesions confirmed coinfection with monkeypox and herpes simplex virus type 2. We emphasize the difficulty in distinguishing between monkeypox virus and herpes simplex virus type 2 based on history and examination alone.
- 14 December 2022
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 107 (6) , 1258-1260
Case Report: Symptomatic Herpes Simplex Virus Type 2 and Monkeypox Coinfection in an Adult Male
A 39-year-old man presented with a history of fatigue, malaise, and rash with varied morphology on his perianal region. Polymerase chain reaction testing of the lesions confirmed coinfection with monkeypox and herpes simplex virus type 2. We emphasize the difficulty in distinguishing between monkeypox virus and herpes simplex virus type 2 based on history and examination alone.
- Open Access
- 2 September 2022
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (7) , 1093-1101
Clinical, microbiological, and genomic characteristics of clade-III Candida auris colonization and infection in southern California, 2019–2022
Background: Candida auris is an emerging fungal pathogen causing outbreaks in healthcare facilities. Five distinctive genomic clades exhibit clade-unique characteristics, highlighting the importance of real-time genomic surveillance and incorporating genotypic information to inform infection prevention practices and treatment algorithms.Methods: Both active and passive surveillance were used to screen hospitalized patients. C. auris polymerase chain reaction (PCR) assay on inguinal-axillary swabs was performed on high-risk patients upon admission. All clinical yeast isolates were identified to the species level. C. auris isolates were characterized by both phenotypic antifungal susceptibility tests and whole-genome sequencing.Results: From late 2019 to early 2022, we identified 45 patients with C. auris. Most had a tracheostomy or were from a facility with a known outbreak. Moreover, 7 patients (15%) were only identified through passive surveillance. Also, 8 (18%) of the patients had a history of severe COVID-19. The overall mortality was 18%. Invasive C. auris infections were identified in 13 patients (29%), 9 (69%) of whom had bloodstream infections. Patients with invasive infection were more likely to have a central line. All C. auris isolates were resistant to fluconazole but susceptible to echinocandins. Genomic analysis showed that 1 dominant clade-III lineage is circulating in Los Angeles, with very limited intrahost and interhost genetic diversity.Conclusions: We have demonstrated that a robust C. auris surveillance program can be established using both active and passive surveillance, with multidisciplinary efforts involving the microbiology laboratory and the hospital epidemiology team. In Los Angeles County, C. auris strains are highly related and echinocandins should be used for empiric therapy.
- 2 September 2022
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (7) , 1093-1101
Open AccessClinical, microbiological, and genomic characteristics of clade-III Candida auris colonization and infection in southern California, 2019–2022
Background: Candida auris is an emerging fungal pathogen causing outbreaks in healthcare facilities. Five distinctive genomic clades exhibit clade-unique characteristics, highlighting the importance of real-time genomic surveillance and incorporating genotypic information to inform infection prevention practices and treatment algorithms.Methods: Both active and passive surveillance were used to screen hospitalized patients. C. auris polymerase chain reaction (PCR) assay on inguinal-axillary swabs was performed on high-risk patients upon admission. All clinical yeast isolates were identified to the species level. C. auris isolates were characterized by both phenotypic antifungal susceptibility tests and whole-genome sequencing.Results: From late 2019 to early 2022, we identified 45 patients with C. auris. Most had a tracheostomy or were from a facility with a known outbreak. Moreover, 7 patients (15%) were only identified through passive surveillance. Also, 8 (18%) of the patients had a history of severe COVID-19. The overall mortality was 18%. Invasive C. auris infections were identified in 13 patients (29%), 9 (69%) of whom had bloodstream infections. Patients with invasive infection were more likely to have a central line. All C. auris isolates were resistant to fluconazole but susceptible to echinocandins. Genomic analysis showed that 1 dominant clade-III lineage is circulating in Los Angeles, with very limited intrahost and interhost genetic diversity.Conclusions: We have demonstrated that a robust C. auris surveillance program can be established using both active and passive surveillance, with multidisciplinary efforts involving the microbiology laboratory and the hospital epidemiology team. In Los Angeles County, C. auris strains are highly related and echinocandins should be used for empiric therapy.